Lightstone Ventures leads Series B round for Catabasis

Catabasis Pharmaceuticals said Friday that it has secured $32.4 million in Series B financing. New investor Lightstone Ventures was the lead investor. Current investors SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures also participated in the round. Headquartered in Cambridge, Mass., Catabasis is a clinical-stage company dedicated to treating inflammatory and metabolic diseases.

North AmericaUSBriefs